for less than 1% of children, and all control group None of study participants reported a serious
results are presented in the clinical results side effect. No study participant withdrew from
summary. the study because of a side effect.
The results from this study did not raise any
safety concern. The side effects reported in this
study are known reactions to the study vaccines.
Figure 3: Side effects in at least 1% of children
How has this study helped patients and researchers?
The results from this study indicate that giving The results from this study have been shared
malaria vaccine together with 2 other childhood with the regulatory agencies for evaluation and,
vaccines is well tolerated and does not impact if approved, will enable health care professionals
the response to the vaccines in children. to give the malaria vaccine together with 2 other
childhood vaccines to children.
Are there plans for further studies?
At the time of preparation of this summary, other The results of any future studies will be available
studies were ongoing to further evaluate the on the websites of European Medicines Agency
malaria vaccine. and/or the United States National Institutes of
Health. Links are provided at the end of the
document.
Where can I find more information about this study?
The detailed title for this research study is:
Phase IIIB randomized, open, controlled, multi-center study to evaluate the immunogenicity and safety of
the RTS,S/AS01 candidate malaria vaccine, when administered as primary vaccination at 6, 7.5 and 9
E
*The use of the term side effects in this summary may be different to that in the Informed Consent or other
documents related to the vaccine.